JPRN-UMIN000011962招募中未知
Study of NK1-receptor antagonist; aprepitant for prevention of nausea and emesis in patients receiving chemotherapy with irinotecan for gastric cancer. - Effect of aprepitant in patient receiving chemotherapy with irinotecan for gastric cancer.
Gastroenterologic Surgery, Kanazawa University0 个研究点目标入组 55 人开始时间: 2013年10月5日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 55
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) patients with serious hepatic insufficiency or renal failure. 2) patients with emesis within 24 hours before first administrating of cisplatin. 3) patients who were administered antiemetic drugs within 48 hours before first administrating of cisplatin. 4) patients with emetic factor except for chemotherapy 5) patient who was intended radiation therapy
研究者
相似试验
招募中
2 期
Efficacy of NK1 receptor antagonist (aprepitant) in the cancer chemotherapies for hematologic malignancies.hematologic malignanciesJPRN-UMIN000006690Kagoshima University Hospital, division of Hematology and Immunology40
已完成
3 期
Four drug anti-emetic studyCTRI/2021/04/032528CI AIIMS250
招募中
不适用
Study of oral neurokinin-1 antagonist, aprepitant for the prevention of nausea and vomiting in patients receiving chemotherapy with irinotecan alone or combination of irinotecan plus cisplatin for unresectable gastric cancergastric cancerJPRN-UMIN000004021Division of Upper Gastroenterology, Department of Internal Medicine, Hyogo College of Medicine80
已完成
不适用
fMRI study on effect of NK1 antagonist (Aprepitant) on cognitive function in normal subjectsSubstance-related disorders, Mood disorders, Anxiety disordersJPRN-UMIN000004381ippon Medical School20
招募中
不适用
Effect of oral neurokinin-1 antagonist, aprepitant for chemotherapy-induced nausea and vomiting in patients with gynecologic cancer receiving carboplatin/paclitaxel chemotherapy.JPRN-UMIN000005317Department of gynecology, Fukuoka University Hospital60